Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Shahin, Gharakhanian"'
Autor:
Julien Pottecher, Francois Raffi, Martine Jandrot-Perrus, Sophie Binay, Andrea Comenducci, Violaine Desort-Henin, Déborah François, Shahin Gharakhanian, Marilyn Labart, Adeline Meilhoc, Elie Toledano, Yannick Pletan, Gilles Avenard, Victor H Sato, GARDEN Investigators
Publikováno v:
PLoS ONE, Vol 19, Iss 6, p e0302897 (2024)
BackgroundGlenzocimab is a novel antithrombotic agent which targets platelet glycoprotein VI (GPVI) and does not induce haemorrhage. SARS-CoV-2 triggers a prothrombotic state and lung injury whose mechanisms include coagulopathy, endothelial dysfunct
Externí odkaz:
https://doaj.org/article/a91527e6dcb1475bae6f6ac3943ece73
Autor:
Shahin, Gharakhanian
Publikováno v:
AIDS. 36:2217-2219
Autor:
Shahin Gharakhanian, Stephane De Wit
Publikováno v:
AIDS (London, England). 36(8)
Autor:
Moises Contreras, Shahin Gharakhanian, Netanya S. Utay, David M. Asmuth, Christopher J. Detzel, Christopher D. Warner
Publikováno v:
Drug development research. 82(7)
COVID-19 manifests as a mild disease in most people but can progress to severe disease in nearly 20% of individuals. Disease progression is likely driven by a cytokine storm, either directly stimulated by SARS-CoV-2 or by increased systemic inflammat
Autor:
Jacques Reynes, Alain Devidas, Béhazine Combadière, Yazdan Yazdanpanah, Patrice Debré, Laurence Weiss, Yasmine Dudoit, Laurent Cotte, Gilles Pialoux, Delphine Joyeux, Gerd Fätkenheuer, Roland Tubiana, Jürgen K. Rockstroh, Odile Launay, Shahin Gharakhanian, Christine Katlama, Vincent Vieillard, Pierre-Marie Girard, Felipe García, José M. Gatell, Brigitte Autran, Anne Simon
Publikováno v:
NPJ vaccines
NPJ vaccines, 2019, 4, pp.1. ⟨10.1038/s41541-019-0117-5⟩
npj Vaccines
NPJ Vaccines
NPJ vaccines, Nature Research 2019, 4 (1), ⟨10.1038/s41541-019-0117-5⟩
NPJ vaccines, Nature Research 2019, 4, pp.1. ⟨10.1038/s41541-019-0117-5⟩
npj Vaccines, Vol 4, Iss 1, Pp 1-9 (2019)
NPJ vaccines, 2019, 4, pp.1. ⟨10.1038/s41541-019-0117-5⟩
npj Vaccines
NPJ Vaccines
NPJ vaccines, Nature Research 2019, 4 (1), ⟨10.1038/s41541-019-0117-5⟩
NPJ vaccines, Nature Research 2019, 4, pp.1. ⟨10.1038/s41541-019-0117-5⟩
npj Vaccines, Vol 4, Iss 1, Pp 1-9 (2019)
VAC-3S is a therapeutic vaccine comprising a highly conserved HIV-gp41 motif coupled with the CRM197 carrier protein. High levels of anti-3S antibodies (Abs) have been associated with improved protection of CD4+ T-cell survival. A previous phase 1 st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b207d27547eeb4edb6cec615217db15e
https://hal.sorbonne-universite.fr/hal-02165946/file/s41541-019-0117-5.pdf
https://hal.sorbonne-universite.fr/hal-02165946/file/s41541-019-0117-5.pdf
Autor:
Vincent, Vieillard, Shahin, Gharakhanian, Olivier, Lucar, Christine, Katlama, Odile, Launay, Brigitte, Autran, Raphael, Ho Tsong Fang, Joël, Crouzet, Robert L, Murphy, Patrice, Debré
Publikováno v:
Oncotarget
The major advances achieved in devising successful combined antiretroviral therapy (cART) have enabled the sustained control of HIV replication. However, this is associated with costly lifelong treatment, partial immune restoration, chronic inflammat
Autor:
Robert S. Kauffman, Eric Lawitz, Lindsay McNair, Nezam H. Afdhal, Gurudatt Chandorkar, Stuart C. Gordon, William M. Lee, Matthew W. Harding, Molly Aalyson, Herbert L. Bonkovsky, Vinod K. Rustgi, John Alam, John G. McHutchison, Leif Bengtsson, Shahin Gharakhanian, Fred Poordad
Publikováno v:
Hepatology. 50:1719-1726
Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavi
Autor:
Christophe, Hézode, Nicole, Forestier, Geoffrey, Dusheiko, Peter, Ferenci, Stanislas, Pol, Tobias, Goeser, Jean-Pierre, Bronowicki, Marc, Bourlière, Shahin, Gharakhanian, Leif, Bengtsson, Lindsay, McNair, Shelley, George, Tara, Kieffer, Ann, Kwong, Robert S, Kauffman, John, Alam, Jean-Michel, Pawlotsky, Stefan, Zeuzem, P, Ferenci
Publikováno v:
New England Journal of Medicine. 360:1839-1850
Background In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained virologic response of 40 to 50%. Telaprevir is a specific inhibitor of t
Autor:
Patrice Callard, Shahin Gharakhanian, Philippe Bonnard, Corinne Amiel, François-Xavier Lescure, Gilles Pialoux, J.-B. Guiard-Schmid
Publikováno v:
Journal of Viral Hepatitis. 14:806-811
Summary. In HIV/hepatitis C virus (HCV)-coinfected patients, it is recommended to repeat liver biopsy every 3 years when anti-HCV treatment is not indicated. We studied fibrosis progression in HIV/HCV-coinfected patients, who were not receiving anti-
Autor:
Yuji Matsuzawa, Jacqueline Capeau, Corinne Vigouroux, Thu-Huyen Nguyên, Tohru Funahashi, Jean-Philippe Bastard, Willy Rozenbaum, Shahin Gharakhanian, Mustapha Maachi, Christiane Coussieu, Iichiro Shimomura
Publikováno v:
AIDS. 17:1503-1511
OBJECTIVES Adipocytokines, secreted by adipose tissue, may regulate fat metabolism, lipid and glucose homeostasis and insulin sensitivity. We analysed the relations between circulating concentrations of adiponectin, leptin, interleukin-6, tumor necro